This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Boceprevir, the combination of ombitasvir-paritaprevir-ritonavir, and telaprevir may slow down how quickly your body processes your calcium channel blocker.
What might happen:
The amount of calcium channel blocker in your blood may increase and cause more side effects than normally expected.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Contact your doctor if you experience any chest discomfort, severe dizziness, fainting, or fast heartbeat.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Victrelis (boceprevir) US prescribing information. Schering Corporation January, 2017.
2.Viekira Pak (ombitasvir, paritaprevir, and ritonavir; dasabuvir) US prescribing information. AbbVie Inc. March, 2017.
3.Incivek (telaprevir) US prescribing information. Vertex Pharmaceuticals Incorporated October, 2013.
4.Lee JE, van Heeswijk R, Alves K, Smith F, Garg V. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother 2011 Oct; 55(10):4569-74.
5.FDA. CDER Application number: 2066190 Viekira Pak (ombitasvir, paritaprevir, ritonavir, dasabuvir) Clinical Pharmacology and Biopharmaceutics Review(s). URL: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206619Orig1s000Clin PharmR.pdf December 19, 2014.